AH Equity Partners Bio II, L.L.C. (Andreessen Marc L, HOROWITZ BENJAMIN A) sold $11.8M of NAUT (indirect holdings)
AH Equity Partners Bio II, L.L.C. sold 5,000,000 indirectly-held shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($11.75M total) across 2 trades on 2026-06-02. Filed jointly with Andreessen Horowitz LSV Fund II, L.P. (10% owner), AH Bio Fund II, L.P. (10% owner), AH Equity Partners LSV II, L.L.C. (10% owner), Andreessen Marc L (10% owner) and HOROWITZ BENJAMIN A (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale adds supply and may trigger short‑term price decline.
Market read
Primary disclosure of a material insider transaction for a micro‑cap biotech.
What to watch
Potential upcoming clinical data releases that could offset sell pressure.
Background
SEC Form 4 filing by AH Equity Partners Bio II, L.L.C. reporting a large insider sale.
Ticker impact
Form 4 disclosed a $11.75M open‑market sale of 5,000,000 shares by a 10% owner.
likely downward pressure as market prices in the large insider sell.
The transaction size is material for a micro‑cap biotech and the seller holds a significant stake.
Market effects
May weigh on other biotech stocks as investors watch insider activity.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
The sale could be a portfolio rebalancing unrelated to company fundamentals.
Key entities
- companyNautilus Biotechnology, Inc.
Biotech firm listed on NASDAQ under ticker NAUT.
- insiderAH Equity Partners Bio II, L.L.C.
10% owner reporting the sale.